Anti‐tumor drug supervision in China from 2010 to 2024: the evolution and prospect of drug review standards
Saved in:
Main Authors: | Ling Tang, Yuanyuan Song, Hong Zhang, Ruimin Hao, Xin Tong, Xing Ai, Jun Ma, Zhimin Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Cancer Communications |
Online Access: | https://doi.org/10.1002/cac2.12630 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Suppression of Tumor Angiogenesis by Nonsteroidal Anti-Inflammatory Drugs: A New Function for Old Drugs
by: Curzio Raegg, et al.
Published: (2001-01-01) -
Reform and Development of Rare Diseases Drug Evaluation and Approval in China
by: HUANG Guo, et al.
Published: (2024-10-01) -
Application of organoids in drug screening of gynecological malignant tumors
by: JIANG Yuanyuan, WEI Wenfei, WU Jingya, LI Huawen
Published: (2024-11-01) -
Applied of bioinformatics in drug discovery and drug development: Bioinformatic analysis 1996-2024
by: Irham Lalu Muhammad, et al.
Published: (2024-01-01) -
Brain-targeting Nanoparticle Drug Delivery Systems for Brain Tumors
by: Yi Zhao, et al.
Published: (2025-01-01)